Eurovet has launched Relaquine 35 mg/ml Oral Gel for Horses - a licensed acepromazine (ACP) in a gel format.
The company says Relaquine can be used to sedate horses for examination and in stressful situations that some horses find hard to deal with such as farriery, box rest, dentistry and clipping where highly-strung horses can cause problems. Relaquine is administered orally or mixed with food and is available as an adjustable syringe format containing 10 ml of gel.
Relaquine is the fourth product launch this year by Eurovet and the company says there is more in the pipeline for 2011.
Relaquine Oral Gel is expected to be available to order from veterinary wholesalers from Monday 16th May. Eurovet is also offering an introductory promotion: for further details contact Eurovet on 01223 257933.
The study "Influence of dietary restriction and low-intensity exercise on weight loss and insulin sensitivity in obese equids" was carried out by Nick Bamford and colleagues at the University of Melbourne’s Faculty of Veterinary and Agricultural Science, in collaboration with Spillers.
A total of 24 obese horses and ponies were randomly divided into two groups; 'restricted diet only' or 'restricted diet plus exercise'. All horses and ponies were fed the same diet of restricted hay (no grazing), a small amount of alfalfa chaff and soya bean meal, and a vitamin and mineral supplement.
The exercise programme, which was designed following feedback from horse owners to help ensure it could be implemented relatively easily in the real world, consisted of 15 minutes of brisk trotting (with a five minute walk before and after) five days per week for 12 weeks.
The 'restricted diet only' group showed an overall reduction in body weight and body condition score. They had increased levels of adiponectin – a hormone produced by fat cells, low levels of which are a risk factor for laminitis. They had decreased baseline insulin, high levels of which have been linked to an increased risk of laminitis, and decreased leptin, high levels of which are associated with obesity.
Although exercise did not increase weight loss, it did produce additional benefits that were not seen in the 'restricted diet only' group, the most important one being improved insulin sensitivity. More insulin sensitive horses and ponies need to produce less insulin in order to control their blood sugar. This is important because high levels of insulin in the blood and/or reduced insulin sensitivity are risk factors for laminitis. Horses and ponies in the exercise group also had decreased levels of ‘serum amyloid A’, a protein that is a marker for inflammation.
Clare Barfoot RNutr, the research and development manager at Spillers said: "Reducing calorie intake and feeding a diet low in starch and sugar should be the priority for overweight horses and ponies. However, the results of this study suggest that exercise may offer additional health benefits for obese horses and ponies and/or those with ‘EMS’ that cannot be achieved by cutting calories and weight loss alone."
Reference
Photo: Spillers/Steve Bardens
Dechra Veterinary Products has launched Myorelax, a guaifenesin 100 mg/ml solution for infusion for horses which, the company says, relaxes skeletal muscles within minutes.
Dechra's Equine Brand Manager Emma Jennings said: "Myorelax is indicated for the induction of muscle relaxation and immobilisation, as an adjunct to balanced anaesthesia.
"We're delighted to launch this product, which can be combined with a number of sedatives and anaesthetics including detomidine, ketamine and propofol plus local and volatile anaesthetics.
"Myorelax is a centrally acting muscle relaxant which is effective within a few minutes and does not affect the animal's respiratory muscles at therapeutic doses. It can be used in combination with a sedative and local anaesthetics for short procedures and together with appropriate general anaesthetics for induction and maintenance of muscle relaxation during anaesthesia."
Dechra says that horses are able to stand within 45 minutes after single administration, and the product can be used in a 'triple drip' protocol for total intravenous anaesthesia.
Myorelax is available in 500 ml bottles from veterinary wholesalers.
For further information, visit www.dechra.co.uk
Zoetis, formerly Pfizer Animal Health has launched Ovatec Plus, which it claims will make equine faecal collection and in-practice worm count testing quicker and easier.
Ovatec Plus is designed to facilitate the in-house detection of worm burdens by enabling the coproscopic examination of parasite eggs, larvae and cysts. Zoetis says the built-in sample collection scoop allows for hands-off, quick, clean sample collection and controlled sample size, while the built-in cap, which can be written on for easy identification, snaps shut to seals the contents safely for contamination-free transport.
The system is based on zinc sulphate flotation technology, with a flotation time of ten minutes to provide rapid analysis. The Ova-Spin feature will break up difficult samples. The positive-locking filter chamber prevents any spill of test samples and reduces operator exposure to potential hazards. The overflow reservoir prevents overfills leaking onto the lab bench.
Zoetis says the high sensitivity and excellent specificity of Ovatec Plus enable informed treatment decisions to be made. A study has shown that samples proving negative with Ovatec Plus provide 95% certainty that the sample is <150epg and 100% certainty that the sample is <250epg, which means treatment may not be necessary1. Samples that prove positive, with one or more eggs seen, can be verified using a quantitative technique if needed, alternatively treatment may be indicated.
Ben Lacey, equine business unit manager at Zoetis, said: "Ovatec Plus is an excellent addition to our equine worm control portfolio. It's ideal for use in many test situations, giving a quick, easy and convenient solution."
To find out more, speak to your Zoetis Account Manager, call 0845 300 8034 or email CustomerSupportUK@zoetis.com.
According to the AHT, there is undisputed evidence that owners, riders and trainers have a poor ability to recognise signs of pain seen when horses are ridden. As a result, problems are labelled as training-related, rider-related, behavioural, or deemed 'normal' for that horse because 'that’s how he’s always gone'.
This, says the AHT, means pain-related problems are often disregarded, the horse continues in work, and the problem gets progressively worse.
Dr Sue Dyson, Head of Clinical Orthopaedics at the AHT, believes it may be easier to educate riders and trainers to recognise changes in facial expression and behaviour rather than lameness. So she and her team set out to develop and test an ethogram to describe facial expressions in ridden horses and to determine whether individuals could interpret and correctly apply the ethogram consistently.
At this stage in the project, they concluded that their ethogram could reliably be used to describe facial expressions of ridden horses by people from different professional backgrounds (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(16)30184-8/fulltext).
In the next stage of the project, Sue and her team sought to demonstrate that the ethogram could be used to identify lameness.
The ethogram was applied blindly by a trained analyst to photographs (n=519) of the head and neck of lame (n=76) and non-lame (n=25) horses acquired during ridden schooling-type work at both trot and canter. These included images of seven lame horses acquired before (n=30 photographs) and after diagnostic analgesia had abolished lameness (n=22 photographs).
A pain score (0-3; 0=normal, 1-3=abnormal) was applied to each feature in the ethogram, based on published descriptions of pain in horses.
A total of 27,407 facial markers were recorded, with those giving the greatest significant difference between lame and sound horses including ears back, eyes partially or fully closed, an open mouth with exposed teeth and being severely above the bit.
Pain scores were higher for lame horses than non-lame horses (p<0.001). Total pain score (p<0.05), total head position score (p<0.01), and total ear score (p<0.01) were reduced in lame horses after abolition of lameness.
Severely ‘above the bit’, twisting the head, asymmetrical position of the bit, ear position (both ears backwards, one ear backwards and one to the side, one ear backwards and one ear forwards) and eye features (exposure of the sclera, the eye partially or completely closed, muscle tension caudal to the eye, an intense stare) were the best indicators of pain.
The researchers concluded that application of the ethogram and pain score could differentiate between lame and non-lame horses. Assessment of facial expression could potentially improve recognition of pain-related gait abnormalities in ridden horses (full paper here: http://www.journalvetbehavior.com/article/S1558-7878(17)30019-9/fulltext)
Sue and her team are now working on the development of a whole horse ethogram and its application to non-lame and lame horses, to help to differentiate between manifestations of conflict behaviour, in response to the demands of the rider, and pain. They are also working towards the development of a practical tool for recognising facial expressions, similar to that of a body condition score chart, which they say could dramatically improve the health and welfare of all horses.
Photo: Signs of pain include ears back (pain score of 3), intense stare, muscle tension and mouth. Courtesy Dr Sue Tyson.
BEVA says it was aware, from both younger members and their employers, that there were some equine fields, for which the association had no courses, where newer graduates were lacking in clinical skills.
The new Equine Practice Fundamentals Programme comprises 10 individual CPD courses with a mix of lectures and hands-on practicals. BEVA says it builds on the broad training delivered by the universities to specifically provide the pragmatic knowledge and hands-on clinical skills needed by those in the early stages of an equine veterinary career.
The content was designed on the back of consultation with over 60 senior practitioners from across BEVA’s membership.
The average senior practitioner rated the likelihood that they would encourage recent graduates to attend the programme as 9/10 and BEVA says feedback on the initial course proposal was highly encouraging.
The courses cover:
David Mountford, Chief Executive of BEVA, said: "Because BEVA doesn’t seek to make a profit on its CPD we can deliver an outstanding programme that is both highly regarded and affordable. We anticipate that the series will become essential CPD for those looking to establish themselves in equine practice, for practices looking to support the development of new staff, and for employers looking to differentiate between candidates."
The first five courses will be running during 2018 and again in 2019 together with the remaining five. The full series of ten courses can be booked at a discounted rate. Alternatively, each course can be booked individually.
For further information visit https://www.beva.org.uk/Home/Education/CPD/The-Fundamentals-of-Equine-Practice
Dilaterol is an oral syrup containing 25 mgs/ml clenbuterol hydrochloride, indicated to treat respiratory disease in horses. It causes intense bronchodilation, inhibits histamine release and increases ciliary mucous clearance. It can be used as a frontline or adjuvant therapy.
Dilaterol is administered via food and comes in a 355 ml bottle with a pump dispenser for easy and accurate dosing.
Emma Jennings, Equine Brand Manager at Dechra said: “We are very pleased to have added Dilaterol to our comprehensive range of equine therapies as it is an established and effective treatment for bronchial conditions.
"It is particularly useful in cases of respiratory allergy, bronchospasm and equine asthma and is already regarded as a valuable tool for veterinary professionals."
Dilaterol will be available to order through wholesalers. For more information, visit www.dechra.co.uk.
Alstoe Animal Health has announced that Vetergesic (buprenorphine), the UK's most commonly used injectable opiate for small animal use, is now registered for use in horses.
Developed and manufactured in the UK, Alstoe took over marketing Vetergesic 11 years ago. Two years ago the company introduced the Multi-Dose Pack, which it says allows veterinary surgeons to manage the larger liquid volumes required in horses more easily.
Alstoe says Vetergesic potentiates sedative drugs for standing sedation or routine premedication and provides profound centrally acting analgesic effects for up to nine hours. In routine procedures, this allows good recoveries and a rapid return to normal behaviour patterns.
Alstoe also says that in a thermal anti-nociceptive study carried out at Bristol University, Vetergesic showed significantly better analgesic effects than butorphanol. Field studies carried out in the UK also confirmed that when combined with a sedative, Vetergesic can provide up to 60 minutes of operating time, with smooth and quick recoveries.
John Nellis of Alstoe said: "We have invested heavily in this product and are confident that the rewards enjoyed by small animal vets will also be appreciated by their equine colleagues. We call Vetergesic 'the thoroughbred of pain management'."
Vetergesic Multidose is available for dogs, cats and horses in a 10 ml vial.
Alstoe offers an hour long explanatory seminar, which can be delivered directly to practice members. An 8 page brochure and 'pocket-sized' dose chart are also available. Further details from Alstoe on: 01347 878606 or email: info@alstoe.co.uk .
To mark today's European Antibiotic Awareness Day 2010, the British Veterinary Association is warning veterinary surgeons in the UK that failure to use antimicrobials responsibly could result in their use being restricted.
The BVA promotes the responsible use of antimicrobials and last year published a poster and guidance for vets: 'Responsible use of antimicrobials in veterinary practice: the 8-point plan'. According to the association, the poster received very positive feedback from across the UK and from the Federation of Veterinarians of Europe (FVE).
Concerns regarding resistance to antimicrobials and antibiotics span both the human and animal medicine fields and in 2008 the Chief Medical Officer called for a ban on the use of certain types of antibiotics in animals in order to protect their activity in humans.
Furthermore some EU Member States already restrict the availability of antimicrobials to veterinary surgeons and adopt a strict formulary approach to the medicines that they can prescribe. The BVA says it is concerned that this trend will reach the UK and the freedom of vets to prescribe according to their clinical judgement will be restricted.
Harvey Locke, President of the BVA, said: "Antimicrobial resistance is an enormous problem for both human and animal health. As veterinary surgeons we have a duty to use these medicines responsibly for the good of animal health and welfare as well as public health.
"The BVA's poster on responsible use should be displayed in veterinary practices across the UK as a constant reminder, and I would urge all vets to refer to it.
"Failure to heed the message of responsible use could result in vets losing the right to prescribe certain medicines, which could have a significant impact on animal health and welfare.
"On Antibiotic Awareness Day our message to vets is clear: use them responsibly or lose them."
AceSedate for horses contains 10mg/ml acepromazine as its active ingredient, which the company says means a lower dose volume is required compared to the non-UK licensed equine acepromazine options available.
The dosage of AceSedate is 0.03-0.10 mg per kg bodyweight, however Jurox recommends that the lower end of the dose range is always selected where possible. It can be administered via intramuscular or slow intravenous injection.
AceSedate is supplied in a multidose vial and the shelf life after opening the immediate packaging is 28 days.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "The launch of AceSedate means injectable acepromazine is now licensed in the UK for horses, giving vets peace-of-mind that a licensed product is now available. It is a welcome addition to our equine anaesthesia, analgesia and sedation portfolio."
For more information, visit: www.jurox.com/uk, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail customerservice@jurox.co.uk.
The first, carried out by Nanna Luthersson and colleagues and published online in the Journal of Equine Veterinary Science in March, evaluated the laminitis risk factors in a group of Danish horses and ponies.1 It confirmed that Cold-blooded type animals <149cm, such as certain native ponies, as well as those being kept on high quality pasture were at an increased risk of developing laminitis for the first time. It also highlighted the important role that a change in grass intake, in terms of both type and amount, may play at any time of the year not only the spring as commonly thought.
The second study, funded in part by the PetPlan Charitable Trust, British Veterinary Association Animal Welfare Foundation Norman Hayward Fund and the Laminitis Trust, was undertaken in conjunction with Nicola Menzies-Gow (Royal Veterinary College) and published online in the Equine Veterinary Journal (EVJ) in August. The study evaluated the risk factors for the development of laminitis prior to the occurrence of the disease.2 It identified that low concentrations of the adipose tissue derived hormone adiponectin, together with high serum insulin concentrations (at rest and as part of a diagnostic test for PPID) may predict an increased risk of future pasture-associated laminitis.
It is hoped that future studies will be able to generate more robust cut off values, which will more accurately predict future laminitis development in an individual animal.
The RVC in collaboration with Waltham is now taking this forward through a study in which these markers are measured regularly, in conjunction with a detailed management assessment, in a group of ponies with no known history of laminitis at the start.
Clare Barfoot RNutr and the research and development manager at Spillers said: "The Danish study gives us important practical facts about the susceptibility of cold-blooded types, and is particularly applicable to natives in the UK. The second study gives hope that there may soon be a test or series of tests that will help predict those at an increased risk of suffering from pasture associated laminitis in the future thereby reducing the number of animals affected by this debilitating condition. In the meantime until we fully understand the condition it is sensible to manage all the risk factors we currently know about, in particular keeping your horse at a healthy weight."
References
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
Zoetis says it is working hard to resolve the situation and apologises for any convenience caused.
For more information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Equibactin vet contains sulfadiazine and trimethoprim, and is indicated for use in the treatment of infections, particularly respiratory tract infections associated with Streptococcus spp. and Staphylococcus aureus; gastrointestinal infections associated with E. coli; urogenital infections associated with beta-hemolytic streptococci; and wound infections and open or drained abscesses associated with Streptococcus spp. and Staphylococcus aureus.
The new product has been designed to provide accurate administration to all sizes of horses or ponies. One syringe provides a complete dose for 600kg bodyweight and is subdivided into 12 markings, to help keep track of dosages.
Dechra Brand Manager Emma Jennings said: "Equibactin vet has a proven antibiotic combination with a synergistic effect2 making it an excellent first line broad spectrum antimicrobial treatment for most Gram positive and negative aerobes.
It can be administered without food which improves the oral bioavailability, offering equine veterinary surgeons a quick and efficient treatment when it comes to targeting these infections that are often experienced in day-to-day practice.
"With its ease of use and three-year shelf life, we anticipate that Equibactin vet will quickly become a popular product when it comes to maintaining equine health."
For more information, visit www.dechra.co.uk/products/equine.
Petplan Equine, the equine insurance provider, has announced the three finalists for the inaugural Petplan Equine Vet of the Year Award.
They are:
The winner of this new people's award will be announced at the glittering 20th annual Animal Health Trust (AHT) Equestrian Awards ceremony to be held at London's Royal Lancaster Hotel on the evening of Thursday 6th November 2008.
Owners and riders were asked nominate their local equine vet for the award if they felt that they were deserving of the recognition that this accolade would bring. A short list was drawn up from the nominations received and an independent panel has selected the finalists from whom the winner will be announced and receive his or her award at the AHT Equestrian Awards.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whittaker of Petplan Equine said: "It has been a privilege to be involved with the AHT Awards over the years. We are particularly excited to be able to recognise the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners. We received some very strong nominations and selecting just three was not easy although, in the case of the finalists it was clear that each consistently went beyond the call of duty."
She added: "Horse welfare is paramount at Petplan Equine and the company is committed to promoting responsible horse ownership, through its charitable contributions, wide range of policies and publications such as the Horse Handbook. This award has been created to give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
The winner will be posted on www.petplanequine.co.uk on Friday 7th November
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
Ceva Animal Health has renamed Tildren, its tiludronate-based bisphosphonate infusion for the treatment of bone spavin in horses, as Equidronate.
Tiludronate has been used to treat bone spavin and navicular disease in Europe for many years and was licensed for bone spavin in the UK in 2008. Ceva says trials published last year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints and is considered to be one of the most common forms of hindlimb lameness in the horse. Horses with bone spavin experience abnormal bone remodeling changes. According to the company, Equidronate helps to modulate the osteoclasts to help prevent excessive bone removal and give the osteoblasts a chance to catch up. This in combination with adjusting levels of exercise helps to harmonise the bone adaptation needed for the horse to perform its athletic duties.
In the trials one in four horses showed marked improvement; two in four showed improvement, which, when combined with other treatment, enabled the horse to resume former levels of activity and one in four horses showed no response.
Ceva Animal Health has produced a range of explanatory leaflets for horse owners on bone spavin, navicular disease and sacroiliac disease, as well as a helpful booklet detailing the discharge procedures for horses that have been treated with Equidronate.
For free copies and for further product information contact your Ceva sales representative, ring Ceva on 01494 781510 or visit the website at http://www.ceva.uk.com/
The Stablelab hand-held reader detects and quantifies the biomarker Serum Amyloid A (SAA), an acute phase protein produced by the liver that increases rapidly and dramatically in response to inflammation.
Zoetis says that by measuring SAA, vets can assess the severity of an infection more quickly, often before clinical symptoms start, and are able to monitor the horse’s response over the course of treatment.1
Zoetis vet Wendy Talbot said: “Zoetis is committed to providing vets and horse owners with the most effective health products to better predict, prevent, detect and treat equine disease.
“The Stablelab test kit enables convenient, off-site testing for quick and accurate detection of a reliable indicator of infection in horses.
“Point-of-care testing is one of the fastest-growing areas of diagnostics and this test is rapidly becoming a standard of care in equine practice. SAA testing will help vets to quickly determine an appropriate course of intervention, positively impacting case outcomes.”
For more information, visit: www.stablelab.com. To place an order, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 (option 3).
The toolkit has been developed in conjunction with the RSPCA and includes a welfare workflow, quick download guides and welfare case forms. It can be downloaded here .
Merry Smith, a BEVA council member who led the project on behalf of BEVA, said: "Welfare assessments can sometimes be intimidating and it’s natural to feel vulnerable, particularly when circumstances are difficult. Our new Welfare Case Toolkit gives you access to the information and resources, even when you are on the road, to support you in dealing with a welfare case."
The interactive Welfare Workflow provides a step-by-step guide to what happens when a vet is called upon to provide an opinion on the health and welfare of the animals involved. It has been produced in a mobile-friendly format or can be printed out and kept in the car. Supporting the Workflow is a series of quick downloads, covering all aspects of the process:
Approach to the welfare case
Letter of instruction
Section 18 of the Animal Welfare Act (2006) certificate
Witness details sheet
Witness statement form
RSPCA vet exam form
Guidance notes on how to complete a vet exam welfare case form
Caroline Allen, Chief Veterinary Officer at the RSPCA said: "Vets are absolutely critical to the work of the RSPCA and while we know many vets get a lot of satisfaction from this work saving animals from cruelty and suffering, we know that this work can sometimes be daunting and the law confusing. We are delighted to have worked with BEVA on providing this guidance and hope it is the first step in us providing more support to vets doing this vital work- we literally couldn't do it without you"
The Welfare Case Toolkit is available free to BEVA members https://www.beva.org.uk/Resources-For-Vets-Practices/Clinical-Practice-Guidance/Welfare-guidance/Welfare-toolkit
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
The Best UK Vets Awards are given to the practices that accumulate the largest number of positive reviews from clients on vethelpdirect.com and any-uk-vet.co.uk over the course of the year.
Penmellyn Vets achieved 839 positive ratings; 200 more than their nearest rivals, reflecting the tremendous level of engagement they have with their clients, something which also shone through in the sentiments expressed in their client reviews.
Penmellyn Vets is an independent practice owned by six veterinary surgeons, who are all based in Cornwall. They have been providing veterinary care to the pets and horses of Cornwall for over 130 years. They still cover their own out of hours’ care and their services include preventative healthcare packages for their cat and dog-owning clients, ‘LifeCare’ and ‘LifeCare+’. The latter grants clients access to unlimited vet and nurse consultations 6 days a week – something that is currently only offered by Penmellyn Vets in Cornwall.
Philip Harris, one of the partners at Penmellyn Vets said: "We are absolutely delighted to have won this award and want to say thank you to each and every one of our clients who took the time to leave a review. And my thanks to the Penmellyn staff for their hard work and commitment to providing the outstanding customer service that has been recognised by this award. I couldn’t be more proud of them. We’re an independent practice and very traditional in many ways, so I think as we’ve grown as a group, with a goal of excellence always in patient care, our values have kept us grounded and very client-centric. We look forward to celebrating the award with our team at the awards ceremony in the coming weeks."
Blacks Vets in Dudley were awarded the Silver award after receiving a very commendable 620 qualifying client reviews.
Tracey Jewkes, Managing Director, said: "We are delighted to have been awarded Silver in the Best UK Vet 2017 Award and would like to take this opportunity to send a heartfelt thank you to our wonderful clients for voting for us again this year. Our consistency at the top of this award for the past 3 years is a reflection of both the calibre and heart Team Blacks give to pets, clients and each other year after year. We could not be more proud of each and every team member here, nor could we feel more privileged to take great care of so many much loved pets in our local community."
Inglis Veterinary Hospital in Dunfermline, Scotland received 358 qualifying reviews and received the Bronze award. They also went on to win the Best Scottish Vet Award 2017.
The full list of winners is:
This year’s winners of the small category awards are:
The Disciplinary Committee heard three charges against Dr Jones.
The first and second charges were that, in March 2018, Dr Jones made signed entries in the passports and made corresponding entries in clinical records of four horses indicating that he had administered an influenza vaccination booster to each horse on 15 March 2018 and in relation to another horse a tetanus booster, when in fact he had administered the vaccination boosters on 21 March 2018, and that his conduct was misleading, dishonest and undermined the integrity of a vaccination process designed to promote animal welfare.
The third charge was that, on or around 21 March 2018, Dr Jones failed to make any entries in the clinical records for a horse in relation to an examination on 21 March 2018.
At the outset of the hearing Dr Jones admitted the facts in the first and second charges, and accepted that his actions were misleading, dishonest and that they undermined the integrity of a vaccination process. However, he disputed certain aspects of the written statements of the College’s witnesses. In particular he wanted his conduct to be taken in the context of the pressures that he was working under on that day, primarily that he was in a stressed state having had to euthanase a valuable stallion at the conclusion of his previous client appointment.
Dr Jones did not admit the third charge, explaining that he did not remember examining the horse on 21 March 2018 as alleged.
Based on Dr Jones' own admissions, the Committee found the first and second charges proven.
Regarding the third charge, the Committee heard evidence from the horse’s owner who said they were present during the examination taking place and the Committee was satisfied that the respondent did examine the horse on 21 March 2018 and that he had a duty to make a brief clinical note on the examination. As Dr Jones admitted that he made no such note, the Committee found the charge to have been proven to the requisite standard.
Having found the charges proven, the Committee then went on to consider whether or not Dr Jones’ proven conduct amounted to serious professional misconduct. The Committee, having considered the aggravating and mitigating factors, found that Dr Jones’ conduct as found proved in relation to both charges one and two, did constitute serious professional misconduct.
However, with regards to charge three, the Committee accepted that the respondent simply forgot that he had examined the horse and, therefore, the Committee was not satisfied that the failure to compile a record entry covering the horse’s examination constituted serious professional misconduct.
The Committee then considered what sanction to impose on Dr Jones in relation to the facts found proven in charges one and two. In doing so it took into account the 78 written testimonials and 4 character witnesses called on behalf of Dr Jones.
Ian Green, who chaired the Committee and spoke on its behalf, said: "The Committee’s decision on sanction has been based on an acceptance that the respondent’s conduct on this occasion was out-of-character, as the evidence of his character witnesses and the contents of the letters submitted in his support by his clients and other veterinary colleagues assert. The Committee also accepts that the respondent self-reported himself to his employer and to the College and has made a full and frank admission of his wrongdoing.
"Consideration was given to whether the sanction of a reprimand and/or warning as to future conduct would adequately reflect the gravity of the misconduct, however, after careful reflection it was concluded that such a sanction could not be justified. The reason is that acts of falsification involve acts of dishonesty by a professional person acting in a professional capacity, and the gravity of the matter arises not simply from the dishonesty but also from the possible consequences of the false certification. It should be clearly understood by members of the veterinary profession that, in appropriate false certification cases, the sanction of removal from the Register is one which may well be imposed."
The Committee therefore decided that suspending Dr Jones from the Register for two months would be the most appropriate sanction.
Severn Edge was formed six years ago with the merger of two long-standing neighbouring practices, and now employs 135 people, including 43 veterinary surgeons.
Mrs Karyn MacKenzie, Director of CVS’ Practice Division, said: "Severn Edge is an impressive practice with an outstanding leadership team and an ambitious and exciting vision for the future which we share. We are delighted to welcome the team to CVS and look forward to working with them to help them build an even more successful future."
Dr John Brentnall BVSc MRCVS, a Director of Severn Edge, will continue in the role of CVS Regional Director. He said: "It was clear from our early discussions that CVS understood what we are trying to achieve. We have embarked on a significant investment programme, including upgrading our surgery at Madeley outside Telford, and the redevelopment of the site of an additional clinic which we have recently acquired in Craven Arms.
"In order for us to continually upgrade our clinics, provide the widest range of career opportunities for our staff and steer our practice through an increasingly competitive world, we believe that the best interests of us all lie in joining forces with CVS. It is known for its interest in equine and farm practice, as well as companion animal practice, and has a policy of significant investment in both infrastructure and staff. We believe it offers the best fit with Severn Edge."
Boehringer Ingelheim Vetmedica has launched Prascend, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushing's Disease.
Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Many horses and ponies with Cushing's Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future.
"We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market."
For further information, visit www.prascend.co.uk or call 01344 746959